127 related articles for article (PubMed ID: 35475537)
1.
Boissière-Michot F; Mollevi C; Baecker V; Crapez E; Jacot W
Int J Mol Med; 2022 Jun; 49(6):. PubMed ID: 35475537
[TBL] [Abstract][Full Text] [Related]
2. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
3. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
4. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Castelló R; Estellés A; Vázquez C; Falcó C; España F; Almenar SM; Fuster C; Aznar J
Clin Chem; 2002 Aug; 48(8):1288-95. PubMed ID: 12142386
[TBL] [Abstract][Full Text] [Related]
5. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
7. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
8. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
9. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
[TBL] [Abstract][Full Text] [Related]
10. mRNA expression of urokinase and plasminogen activator inhibitor-1 in human crescentic glomerulonephritis.
Lee HS; Park SY; Moon KC; Hong HK; Song CY; Hong SY
Histopathology; 2001 Aug; 39(2):203-9. PubMed ID: 11493338
[TBL] [Abstract][Full Text] [Related]
11. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
12. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
Hildenbrand R; Glienke W; Magdolen V; Graeff H; Stutte HJ; Schmitt M
Histochem Cell Biol; 1998 Jul; 110(1):27-32. PubMed ID: 9681686
[TBL] [Abstract][Full Text] [Related]
13. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
15. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
16. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
Qin W; Zhu W; Wagner-Mann C; Sauter ER
Ann Surg Oncol; 2003 Oct; 10(8):948-53. PubMed ID: 14527916
[TBL] [Abstract][Full Text] [Related]
17. Human endothelial cell migration is stimulated by urokinase plasminogen activator:plasminogen activator inhibitor 1 complex released from endometrial stromal cells stimulated with transforming growth factor beta1; possible mechanism for paracrine stimulation of endometrial angiogenesis.
Sandberg T; Casslén B; Gustavsson B; Benraad TJ
Biol Reprod; 1998 Oct; 59(4):759-67. PubMed ID: 9746723
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
[TBL] [Abstract][Full Text] [Related]
19. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Lamy PJ; Verjat T; Servanton AC; Paye M; Leissner P; Mougin B
Am J Clin Pathol; 2007 Sep; 128(3):404-13. PubMed ID: 17709314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]